Meribank Biotech Co (ROCO:4724) ROCE % : -4.90% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Meribank Biotech Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -4.90%.

Meribank Biotech Co ROCE % Historical Data

The historical data trend for Meribank Biotech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co ROCE % Chart

Meribank Biotech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-8.69

-13.23

-12.87

-15.44

-5.37

Meribank Biotech Co Semi-Annual Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial									-13.56	-17.53	-16.88	-9.40	-4.90

Meribank Biotech Co ROCE % Calculation

Meribank Biotech Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-90.85	/	( ( (1062.008 - 126.911)	+	(2681.936 - 232.226) )	/ 2 )
	=	-90.85	/	( (935.097	+	2449.71)	/ 2 )
	=	-90.85	/	1692.4035
	=	-5.37 %

Meribank Biotech Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-86.636	/	( ( (1220.942 - 133.934)	+	(2681.936 - 232.226) )	/ 2 )
	=	-86.636	/	( ( 1087.008	+	2449.71 )	/ 2 )
	=	-86.636	/	1768.359
	=	-4.90 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Meribank Biotech Co (ROCO:4724) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Meribank Biotech Co ROCE % Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Meribank Biotech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493

Website

http://www.meribank.com.tw

Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co Headlines

No Headlines